Use of CA-125 in clinical trial evaluation o... [Clin Cancer Res. 2004] - PubMed

Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop. [Gynecol Oncol. 2007]
Clinical trial endpoints in ovarian cancer: report of an FDA/ASCO/AACR Public Workshop.
Bast RC, Thigpen JT, Arbuck SG, Basen-Engquist K, Burke LB, Freedman R, Horning SJ, Ozols R, Rustin GJ, Spriggs D, et al. Gynecol Oncol. 2007 Nov; 107(2):173-6.
Review Use of CA-125 to assess response to new agents in ovarian cancer trials. [J Clin Oncol. 2003]
Review Use of CA-125 to assess response to new agents in ovarian cancer trials.
Rustin GJ. J Clin Oncol. 2003 May 15; 21(10 Suppl):187s-193s.
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples. [Cancer Prev Res (Phila). 2011]
The sine qua non of discovering novel biomarkers for early detection of ovarian cancer: carefully selected preclinical samples.
Jacobs I, Menon U. Cancer Prev Res (Phila). 2011 Mar; 4(3):299-302.
Monitoring ovarian cancer: CA125 trial stirs controversy. [J Natl Cancer Inst. 2009]
Monitoring ovarian cancer: CA125 trial stirs controversy.
Chitale R. J Natl Cancer Inst. 2009 Sep 16; 101(18):1233-5. Epub 2009 Sep 8.
Review Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management. [Dan Med Bull. 2006]
Review Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management.
Grønlund B. Dan Med Bull. 2006 Aug; 53(3):232-57.

Applications of protein microarrays for biomarker discovery. [Proteomics Clin Appl. 2008]
Applications of protein microarrays for biomarker discovery.
Ramachandran N, Srivastava S, Labaer J. Proteomics Clin Appl. 2008 Oct; 2(10-11):1444-59. Epub 2008 Sep 10.
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. [BMC Cancer. 2010]
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
Mahner S, Woelber L, Eulenburg C, Schwarz J, Carney W, Jaenicke F, Milde-Langosch K, Mueller V. BMC Cancer. 2010 Apr 13; 10:139. Epub 2010 Apr 13.
Mucins in ovarian cancer diagnosis and therapy. [J Ovarian Res. 2009]
Mucins in ovarian cancer diagnosis and therapy.
Chauhan SC, Kumar D, Jaggi M. J Ovarian Res. 2009 Dec 24; 2:21. Epub 2009 Dec 24.

Related Citations
Calculated set of PubMed citations closely related to the selected article(s) retrieved using a word weight algorithm. Related articles are displayed in ranked order from most to least relevant, with the “linked from” citation displayed first.
Cited in PMC
Full-text articles in the PubMed Central Database that cite the current articles.

Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian ...
Use of CA-125 in clinical trial evaluation of new therapeutic drugs for ovarian cancer.
Clin Cancer Res. 2004 Jun 1 ;10(11):3919-26.

PubMed
Discrepancies in clinical laboratory testing of eligibility for trastuzumab ther...
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message.
J Clin Oncol. 2001 May 15 ;19(10):2714-21.

PubMed
Dendritic cells: development, function and potential use for cancer immunotherap...
Dendritic cells: development, function and potential use for cancer immunotherapy.
Blood Rev. 1999 Mar ;13(1):51-64.

PubMed
Inhibition of breast cancer metastasis by selective synthetic polypeptide agains...
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4.
Cancer Res. 2004 Jun 15 ;64(12):4302-8.

PubMed
Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their...
Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors.
Breast Cancer Res. 2000 ;2(3):191-6. Epub 2000 Mar 25 .

PubMed

Your browsing activity is empty.

Activity recording is turned off.

PubMed